These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29941531)

  • 1. FDA approves licensing of erenumab-aooe to prevent migraine.
    Traynor K
    Am J Health Syst Pharm; 2018 Jul; 75(13):929-930. PubMed ID: 29941531
    [No Abstract]   [Full Text] [Related]  

  • 2. Erenumab: First Global Approval.
    Markham A
    Drugs; 2018 Jul; 78(11):1157-1161. PubMed ID: 29968151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aimovig for Migraine Prevention: The New Kid May Have Trouble Fitting in.
    Reinke T
    Manag Care; 2018 Jul; 27(7):10-11. PubMed ID: 29989892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erenumab (Aimovig) for migraine prevention.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):101-103. PubMed ID: 29913472
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
    Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
    Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications Approved for Preventing Migraine Headaches.
    Spindler BL; Ryan M
    Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGRP Antibodies as Prophylaxis in Migraine.
    Edvinsson L
    Cell; 2018 Dec; 175(7):1719. PubMed ID: 30550780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 9. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.
    Szperka CL; VanderPluym J; Orr SL; Oakley CB; Qubty W; Patniyot I; Lagman-Bartolome AM; Morris C; Gautreaux J; Victorio MC; Hagler S; Narula S; Candee MS; Cleves-Bayon C; Rao R; Fryer RH; Bicknese AR; Yonker M; Hershey AD; Powers SW; Goadsby PJ; Gelfand AA
    Headache; 2018 Nov; 58(10):1658-1669. PubMed ID: 30324723
    [No Abstract]   [Full Text] [Related]  

  • 11. Fremanezumab: First Global Approval.
    Hoy SM
    Drugs; 2018 Nov; 78(17):1829-1834. PubMed ID: 30406901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
    Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
    Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
    Naegel S; Burow P; Holle D; Stoevesandt D; Heintz S; Thaele A; Zierz S; Kraya T
    Headache; 2021 Apr; 61(4):694-696. PubMed ID: 33779998
    [No Abstract]   [Full Text] [Related]  

  • 14. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.
    Evans RW
    Headache; 2019 Sep; 59(8):1360-1364. PubMed ID: 31310337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CGRP antibodies: a new approach to migraine prevention.
    Reuter U
    Lancet Neurol; 2014 Sep; 13(9):857-9. PubMed ID: 25127171
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA approves Topamax for migraine prevention in adolescents.
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):191. PubMed ID: 25011147
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
    Sussman M; Benner J; Neumann P; Menzin J
    Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site of effect of LY2951742 for migraine prophylaxis.
    Tfelt-Hansen P
    Lancet Neurol; 2015 Jan; 14(1):31-2. PubMed ID: 25496894
    [No Abstract]   [Full Text] [Related]  

  • 19. Eptinezumab (Vyepti) for migraine prevention.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):85-87. PubMed ID: 32555116
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
    de Hoon J; Van Hecken A; Vandermeulen C; Yan L; Smith B; Chen JS; Bautista E; Hamilton L; Waksman J; Vu T; Vargas G
    Clin Pharmacol Ther; 2018 May; 103(5):815-825. PubMed ID: 28736918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.